Akso Health Group — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2023, compared with fiscal years ended March 31, 2022 and 2021. Although the request references 2022 Q4, this filing is an annual report and does not provide standalone fourth-quarter results.
Business context
The company had shifted from online lending and social e-commerce toward healthcare products and services. In FY2023, medical-device sales—including COVID-19 antigen tests, defibrillators and anesthesia laryngoscopes—accounted for all reported revenue. The company also described plans for U.S. cancer-treatment and radiation-oncology centers, but had not established that these plans were generating revenue. In May 2023, it completed a $215,000 sale of entities associated with its social e-commerce business.
Financial performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $13.19 million | $6.00 million |
| Gross profit | $1.27 million | $0.61 million |
| Gross margin | 9.6% | 10.1% |
| Operating expenses | $15.54 million | $3.87 million |
| Loss from continuing operations | $13.08 million | $4.10 million |
| Net loss | $1.25 million | $16.85 million |
| Cash and cash equivalents at year-end | $7.92 million | $18.43 million |
| Working capital, excluding amounts due from related parties | $8.8 million | $12.2 million |
- Revenue increased 119.7%, but gross margin edged down. General and administrative expense rose to $15.53 million from $2.67 million; management attributed the increase primarily to provisions for uncollected receivables.
- The cash-flow statement reports a $8.27 million provision for doubtful accounts. Accounts receivable was $7.70 million net of a stated $0.40 million allowance; the relationship between these amounts is not clear from the filing text.
- FY2023 net loss was substantially smaller than FY2022 despite a larger continuing-operations loss, because discontinued operations reported $11.84 million of income versus a $12.75 million loss. Discontinued-operations results included $12.89 million of other income; the source of this item is not clearly explained in the supplied text.
- Operating activities used $3.25 million of cash. Investing activities provided $18.47 million, including collection of a $20 million loan receivable; financing activities used $27.51 million, principally for repayment of related-party debt.
- At March 31, 2023, total assets were $20.46 million, total liabilities $11.62 million and total equity $8.84 million. Related-party amounts due were $9.69 million, including $7.69 million principal and $0.11 million accrued interest owed to SOS Information Technology New York and a $2.0 million interest-free loan from Webao Limited.
Outlook, risks and unusual items
- Going concern: The auditor reported substantial doubt about the company’s ability to continue as a going concern, citing FY2023 and FY2022 losses and operating cash outflows. Management said available resources would be sufficient for the next 12 months; the auditor’s opinion did not modify the financial statements for this uncertainty.
- Business plans: Management discussed future healthcare growth, including planned radiation-oncology centers and vaccine research centers, but gave no quantified revenue, earnings or capital-spending guidance. A planned $12.7 million equipment purchase for oncology operations was terminated in February 2022 and the prepayment was refunded.
- Concentration: One supplier represented 97.3% of FY2023 purchases. Three customers represented 59.5%, 11.1% and 10.1% of revenue, respectively. The company reported no long-term purchase or sales contracts.
- Regulatory and execution risks: The filing discusses PRC data, cybersecurity, overseas-listing and foreign-exchange rules, as well as U.S. medical-device and healthcare regulation. It states that the Class III medical-device operating license expired on March 2, 2022, while elsewhere stating that required licenses were obtained; the current authorization status should be confirmed.
- Audit and controls: The financial statements received an unqualified U.S. GAAP audit opinion, with no critical audit matters. The auditor highlighted significant related-party transactions and cautioned they cannot be presumed to be at arm’s length. Management reported effective disclosure controls and internal control over financial reporting; no auditor attestation on internal controls was provided.
- Other: The company reported 12 full-time employees at March 31, 2023 and no dividends after FY2019. The filing also says the social e-commerce disposal closed in May 2023; statements about the entities and VIEs retained or disposed should be reconciled across the filing.
Important facts for investors to verify
- Whether the expired Class III license was renewed and which medical-device licenses and permits were valid during and after FY2023.
- The recoverability, aging and customer concentration of the $7.70 million net receivable, and the basis for the doubtful-account provision.
- The nature of the $12.89 million of other income in discontinued operations and whether it is recurring or cash-generating.
- The company’s liquidity plan, debt repayment terms and ability to fund operations given the auditor’s going-concern warning.
- The precise scope and financial impact of the May 2023 $215,000 disposal, including which subsidiaries, VIEs, assets and liabilities transferred.
- Potential dilution from 6.34 million outstanding warrants covering 19.02 million ordinary shares, exercisable at $3.00 per warrant.